4,836 Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) Acquired by Tema Etfs LLC

Tema Etfs LLC purchased a new position in Scholar Rock Holding Co. (NASDAQ:SRRK) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 4,836 shares of the company’s stock, valued at approximately $209,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. FMR LLC grew its holdings in shares of Scholar Rock by 33.7% in the 4th quarter. FMR LLC now owns 13,635,261 shares of the company’s stock worth $589,316,000 after acquiring an additional 3,439,215 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Scholar Rock by 7.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,283,421 shares of the company’s stock valued at $401,231,000 after buying an additional 629,315 shares in the last quarter. Vanguard Group Inc. lifted its stake in Scholar Rock by 17.6% in the 4th quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company’s stock valued at $205,013,000 after buying an additional 708,817 shares in the last quarter. Marshall Wace LLP lifted its stake in Scholar Rock by 1,283.7% in the 4th quarter. Marshall Wace LLP now owns 2,945,408 shares of the company’s stock valued at $127,301,000 after buying an additional 2,732,546 shares in the last quarter. Finally, Bellevue Group AG lifted its stake in Scholar Rock by 16.2% in the 4th quarter. Bellevue Group AG now owns 2,510,690 shares of the company’s stock valued at $108,512,000 after buying an additional 349,487 shares in the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Insiders Place Their Bets

In other Scholar Rock news, CFO Edward H. Myles sold 7,809 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total transaction of $287,605.47. Following the transaction, the chief financial officer now owns 140,740 shares of the company’s stock, valued at $5,183,454.20. This represents a 5.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Mo Qatanani sold 68,510 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $37.40, for a total value of $2,562,274.00. Following the transaction, the insider now directly owns 111,084 shares in the company, valued at approximately $4,154,541.60. This represents a 38.15% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 255,231 shares of company stock valued at $9,220,236 in the last quarter. 13.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Separately, Wedbush reaffirmed an “outperform” rating and issued a $50.00 target price on shares of Scholar Rock in a research note on Wednesday, May 14th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $42.67.

Scholar Rock Price Performance

SRRK stock opened at $30.55 on Monday. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The stock’s 50 day moving average price is $31.19 and its 200 day moving average price is $35.96. The firm has a market cap of $2.90 billion, a P/E ratio of -13.00 and a beta of 0.37.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.04). During the same period in the prior year, the firm earned ($0.59) earnings per share. On average, sell-side analysts expect that Scholar Rock Holding Co. will post -2.42 earnings per share for the current fiscal year.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.